Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

nce upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we beli
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BEIJING , March 27, 2015 ... the "Company") (NYSE: CCM ), a leading ... the largest network of radiotherapy and diagnostic imaging ... announced the signing of a purchase agreement under ... wholly owned subsidiary of the Company, agreed to ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... 2011 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, ... the companies have begun enrolling patients in a ... (sorafenib) tablets in combination with the oral chemotherapeutic ... treatment of patients with advanced breast cancer. This ...
... OSAKA, Japan, February 23, 2011 Takeda Pharmaceutical ... Research & Development Center, Inc. U.S., submitted a ... and Drug Administration (FDA) for an investigational fixed-dose ... the treatment of hypertension, or high blood pressure. ...
Cached Medicine Technology:Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 2Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 3Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 4Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 5Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 7Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 2Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 3
(Date:3/28/2015)... (PRWEB) March 28, 2015 Could genetic ... a new study by researchers at the ... Produced with the support of the Coffee and Caffeine ... Molecular Psychiatry this past fall, the study—one of several ... of genomic data from more than 120,000 regular coffee ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site ... their Las Vegas warehouse, located at 4606 Andrews St. Suite ... of equipment from hospitals and surgery centers from around the ... , Buyers will find items of all types including anesthesia, ... said Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... prime minister Jose Socrates is smiling. His move to lift a ... voting doing so in favor of the ban being lifted or, ... and Poland- strong catholic nations that prohibit abortion or destruction of ... abort can face up to 3 years prison term and those ...
... monitored more carefully according to reports sounded at the ... a higher risk of giving birth to still-born babies, than ... Yale School of Medicine, who put forward results made after ... ,It was seen that the risk of intrauterine fetal ...
... increases a woman’s risk of becoming infected with HIV, ... edition of The Journal of Infectious Diseases (now online). ... sexually transmitted infections increase the risk of transmission and ... of Trichomonas vaginalis per year worldwide, there are few ...
... alloy surfaces containing at least 90 per cent copper completely ... of the pathogen-killing// properties of the metal. ,The ... on the mix of metals they use to coat the ... better means of eliminating E coli contamination in their products. ...
... The South African AIDS Vaccine Initiative (SAAVI) and the HIV ... of a Phase IIb study utilizing// Merck’s adenovirus trivalent (Ad5 ... and women over a year, and expect the study to ... (HVTN 502) began enrolling in North and South America, the ...
... Researchers at Cold Spring Harbor Laboratory (CSHL) have solved ... critical tumor suppressor gene, but have revealed// a master ... targeted and effective cancer therapy in the future," said ... by Mills, was published in the February issue of ...
Cached Medicine News:Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 2Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 3Health News:Copper Alloys Surfaces Touted As Pathogen Killers 2Health News:Largest Ever African HIV Vaccine Trial Opens in South Africa 2Health News:Scientists Discover New Gene 2
... Clinical is an open platform for clinical diagnostic ... deck sizes of 75, 100, 150 and ... for your laboratory space and throughput requirements. Tecan ... to allow new applications and to evolve the ...
... maximum productivity, and proven reliability, Sorvall ... fully automatic cell washing and centrifugation ... 80-second wash cycle for stat testing, ... and standardized, reproducible procedures. High reliability, ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
... model centrifuge. High throughput, refrigeration maintains ... with all windshield rotors, lifetime reproducibility, ... a remote personal computer or laboratory ... imbalance detection and shut down, armor ...
Medicine Products: